healthcare sector in india monthly update september 2012

7/29/2019 Healthcare Sector in India Monthly Update September 2012

http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 1/13

Healthcare Sector in India

Monthly Update

September 2012



Top Story

348 drugs to come under NLEM

Indian government has for the first time decided to put a price ceiling on essential drugs that will bring relief to huge section of population. 348 such drugs have been identified by a

group of ministers, the proposal of which has been passed on 27th Sep 2012. Drugs that will

soon come under the National List of Essential Medicines (NLEM) include some of the most

critical disease medications like AIDS and cancer apart from a multitude of painkillers, anti‐

tuberculosis drugs, sedatives, lipid lowering agents and steroids. The identified drugs that

omprise 60% of domestic market will be sold at a price fixed by the government once it getsc

the approval of the cabinet.

The initiative by the Indian government is praise worthy but its speedy implementation is

what will bring out the true effectiveness of the plan. Unnecessary delays due to bureaucratic

involvement could ruin the impact of the initiative. Thus, the cabinet and group of ministersmust quicken the proposal assessment for mass benefit.

News Update

General

Electronic health cards to be launched by Prime India

Chennai based medical tourism and healthcare recruitment company Prime India Healthcare

Pvt. Ltd. is in plans to launch electronic health cards. The health card will be used todocument patient disease and health records of the patient as well as his family. The

electronic health cards that come with a USB drive would be highly beneficial for doctors to

administer the right tre with minimum loss of time.atment

Prime India is already providing the health cards to foreign clients as part of its medical

tourism business and is now eager to launch the same for Indian patients through

collaboration with hospitals, pharmacy retail chains and beauty wellness centres. The

product will be launched first in Chennai within a month and 20 other cities soon after. In 3‐4

months time it is expected to be launched in 7 cities inclusive of top metro cities and tier II

towns.

BCG Group to invest on healthcare facilities development

The healthcare division of Kochi based BCG Group; BCG Healthcare is in plans to develop 2

healthcare projects worth INR 3.35 bn. The healthcare division is eager to set up a health

village and a super specialty hospital at Ernakulam in Kochi. The healthcare village valued to

e approximately INR 2.25 bn has been specifically conceived for the aged in Kerala that

orms almost 13% of the state population.

b

f

Healthcare Sector – Monthly Update



The village will be providing traditional healing, cultural facilities and a club house for

recreation. On the other hand BCG has already completed the construction of 100‐bed super

specialty hospital at Palarivattom in Kochi that is approximately valued at INR 1.1 bn. The

ealthcare village is expected to be completed by 2015 while the multispecialty hospital wille completed in 2013.

hb

LifeCell partners with Sequel Logistics

Chennai based the stem cell bank LifeCell International has entered into collaboration with

Sequel Logistics for personalized delivery service of the umbilical cord blood and tissue

samples. Sequel will aid in shipment of stem cells of new born through its partner airlines to

LifeCell's processing and storage facility in Chennai. The shipment will be completed within

24 hours from metro cities and 36 hours from non‐metro cities. The partnership has been

etched out specifically to avoid the long wait hours at airports.

ifeCell will have provision of the service throughout its country wide network in over 100L

cities and towns.

Stem cells have to be sent to the processing and storage facility within 48 hours in order to

chieve the highest quality stem cells. The partnership happens to be first of its kind which is

xpected to help LifeCell reap the benefits of a speedy transport facility.

a

e

News Update

Regulatory 92 drugs to be pulled out from OTC segment

The Drugs and Cosmetics Rules has notified a new schedule H1 to include over the counter

(OTC) drugs that Indians are gradually becoming resistant to or could become resistant to.

The H1 schedule comprises of 92 such antibiotic and anti‐tuberculosis drugs that will be

restricted and would be made available only on presentation of prescription. The Drug

Controller General has already brought the issue to the notice of Union Health Ministry that

will take upon the necessary action.

AIIMS conducting clinical trial of vivax malaria vaccine

AIIMS has been conducting clinical trail of vivax malaria vaccine for its malaria afflicted

patients. The synthetic malaria vaccination that AIIMS has been administering to its patientswas launched by a private pharmaceutical company on 25th April 2012 slated as the World

Malaria Day. The vaccine is not yet available in the open market and is being administered

only to patients admitted in AIIMS emergency. 300 such malaria afflicted patients have been

administered the vaccine, the clinical trial results of which are being kept undisclosed by the

h

ospital.




Depending on the results of the trial the vaccine will be made available in government

hospitals at subsidized rates. The vaccination is expected to bring about a welcome change

for patients since the disease till date has no dependable medication.

DBT funds inStem for its research initiative

The Department of Biotechnology (DBT) will be investing INR 950 mn in collaboration with

National Centre for Biological Sciences (NCBS) and Tata Institute of Fundamental Research

for a new initiative by the Institute for Stem Cell Biology and Regenerative Medicine

(inStem).

inStem is being funded for its initiative in the area of chemical biology and molecular

therapeutics in Bengaluru. inStem – NCBS would be collaborating with UK based University

of Cambridge for carrying out research in cancer and biomedical research.

HLL initiates

fair

price

outlet

at

Government

Eye

Hospital

HLL Lifecare, a mini ratna public sector undertaking in collaboration with Kerala state

government has established a fair price ophthalmic products outlet at Regional Institute of

Ophthalmology. The outlet will be supplying products like spectacles, lenses and frames with

a rebate in the range of 20% to 60% in comparison to open market prices.

Non‐existence of any price regulation for ophthalmic products where prices are fixed as per

the private players, there was urgent need of ophthalmic products subsidization. The

company that strives to provide quality products at affordable prices will be a boon for the

poor.

News Update

Expansion Plans Wockhardt launches generic anti depressant

Wockhardt has acquired approval for marketing Bupropion HCl tablets from United States

Food & Drug Administration (US FDA). The anti depressant drug is the generic form of

Wellbutrin® SR that is marketed in the USA by GlaxoSmithKline. Following the approval,

Wockhardt plans to launch the product with immediate effect. The pharmaceutical and

iotechnology major developed the anti depressant drug technology in‐house andbmanufactured the same at its Waluj facility in Maharashtra.

The approval sums up to Wockhardt’s 6th Abbreviated New Drug Application (ANDA)

approval within a phase of 2 weeks and the generic drug happens to be one of Wockhardt’s

product based on extended‐release technology. Global rise in the number of depression

patients is facilitating companies to launch anti depressants especially generic versions that

have 2‐way benefit for pharma companies as well as patients.




E-MAGIC® Plus stent forays into India

Opto Eurocor Healthcare Limited (OEHL) has launched its first Sirolimus Drug Eluting Stent

(DES), E‐MAGIC® Plus following the approval from Drug Controller General of India (DCGI).

he product launched by OECL has a choice of 2 drug coatings. The launch of the product o

Tmakes OECL one of the very few c mpanies to have dual drug coating DES product.

The stent has particularly been designed with an extra edge with soft tip technology to

provide smooth access to the lesion site ensuring minimal trauma to the vessel wall. The

newly launched product will bring relief to patients as the stent will help in reducing drug

onsumption significantly. The innovation by OEHL will help patients in India to opt for

etter products that would otherwise have to be imported.

c

b

Osmotica forms an alliance with Panacea Biotec

Wilmington based Osmotica Pharmaceutical Corp. has joined hands with Indian

biotechnology company Panacea Biotec Ltd. with the aim to launch more drugs in NorthAmerican market. The alliance will see Panacea focusing on product development and

anufacturing while Osmotica will deal in product registration, legal matters, attainingm

approvals for the drugs and preparing for launch of products in the market.

The deal that was signed on 11th Sep, 2012 will be beneficial for both the companies as both

can stimulate their business extensively. The partnership will help them in tapping the US

arket that is currently projecting an ever increasing demand for high‐quality

harmaceutical products.

m

p

Stem cell research institute to be set up in Surat

The Gujarat state health minister, Jay Narayan Vyas announced the setting up of a Stem CellResearch Institute in Surat at the 2‐day Regional Science Congress meet. The research

institute has been estimated to be approximately worth INR 1 bn and is expected to start

peration by the end of 2013. The research institute at Surat is being set up in the framework o

of Stem Cell Research at Vellore, Tamil Nadu but will be equipped with latest facilities.

Stem cell therapy known to be beneficial for treatment of wide array of critical ailments like

heart ailments, kidney disorders, blood cancer, and thalassaemia is getting prominence in

ndian medical circuit. The Surat research institute that is being financed by the health

epartment will thus be making treatments of such critical diseases accessible.

I

d


Trivitron inks

pact

with

Johari

Chennai based Trivitron Healthcare has entered into a strategic alliance with Jodhpur based

Johari Digital Healthcare to capture global medical devices market. The allies will engage

themselves in manufacture and marketing of physiotherapy, diagnostic care products and

also focus on acquiring patents in physiotherapy genre. The joint venture has been labeled as

Johari Trivitron Medical Innovations Pvt. Ltd. that would look into contract designing and

engineering of the products. The firm would also carry out contract R&D from global

partners. The venture will be established at Trivitron Research Park within IIT Madras.



The products are being designed keeping India, South and South East Asia, Middle East and

frican geographies in mind which demand cost effective high quality products. The deal will

ee Johari manufacturing the products and Trivitron dealing with its marketing and sales.

A

s

NVP invests in Thyrocare Technologies

Norwest Venture Partners (NVP) has invested INR 1.2 bn in Mumbai based Thyrocare

Technologies. As per the deal structure, the investment will bring in NVP’s managing director

ohil Chand as Thyrocare’s board member. The investment will initiate Thyrocare to exploreS

global markets for its medical diagnostic products.

Thyrocare has its presence through a network of 20,000 service centers across 1,000 cities

nd towns, and 100,000 doctors through 600 franchisees. Its wide presence is expected to be

ccelerated further to reach globally with the new investment.

a

a

Industry Expert Speak

DBT funds inStem for its research initiative - Professor Ashok Venkitaraman, Ursula Zoellner, professor of Cancer Research, University of Cambridge and director, Medical Research Council Cancer Cell Unit “The research will now improve our fundamental understanding of the cellular abnormalities

hat cause human diseases like cancer but also to translate this information for the benefit of

atients”

t

p

Trivitron inks

pact

with

Johari

-Dr. GSK Velu, Founder and MD of Trivitron Healthcare

This partnership is an important step towards taking Indian medical technology solutions at

global level."

"

a

Transaction Detail (Jul – Sep 2012)

Date Buyer Target Deal Size

(INR mn) % stake Deal Status

Type of

Transaction

27th Sep

2012

Norwest Venture

Partners

Thyrocare

Technologies1200 10% Completed Private Equity




12th Sep2012

Avigo CapitalPartners

Super ReligareLaboratories

2,916.79 N.A. Planned Private Equity

12th Sep2012

IndoUS VenturePartners

Vyome

Biosciences Pvt Ltd.

185 N.A. Planned Private Equity

11th Sep2012

Norwest VenturePartners

ThyrocareTechnologies

Ltd1166.71 10% Planned Private Equity

5th Sep

2012

Norwest

Venture

Partners

NationWide

PrimaryHealthcare

Services Pvt.Ltd.

250 N.A. Completed Private Equity

3 g0th Au2012

Hospira

OrchidChemicals and

P sharmaceutical

Ltd.Penicillin and

Penem APIbusiness

11125.89 100% Completed Acquisition

2 g9th Au2012

PfizerStrides ArcolabInjectable Drug

Unit

94600 100% Planned Acquisition

23 grd Au

2012

India

InnovationFund

&

Indian AngelNetwork

Consure

MedicalN.A. N.A. Completed Private Equity

21st Aug2012

India EquityPartners

Axiss Dental N.A. N.A. Planned Private Equity

1 g3th Au2012

Somerset IndusCapital

Partners

Express ClinicsPvt. Ltd.

N.A. N.A. Completed Private Equity

1 g3th Au

2012

Goldman Sachs&

New EnterpriseAssociates

Nova MedicalCentres

2969.35 N.A. Completed Private Equity




1 g3th Au2012

Sun

PharmaceuticalIndustries Ltd.

Taro

PharmaceuticalIndustries

32,552.9 34% Planned M&A

30th Jul2012

Sequoia Capital

Practo

TechnologiesPvt. Ltd.


2 l3rd Ju2012

Signet Healthcare

Partners

ClarisLifesciences

227.6 2.20 Completed Private Equity

19th Jul

2012

Medtronic Inc.Trivitron

Healthcare

5498.70 N.A. Planned Private Equity

13th Jul2012

EvolvenceIndia Life

Sciences Fund

Dr. Agarwal'sHealthcare

600 25 Completed Private Equity

4th Jul

2012

RajasthanVenture Capital

Fund

International

OncologyServices Pvt.

Ltd.


Annual Financial Results – Revenue (INR mn) – Major Healthcare

Companies Companies FY ’09 FY ’10 FY ’11 FY’ 12

Biocon Ltd. 16,492.50 23,932.70 27,947.70 21,483.0

Blue Star Ltd. 25,026.2 25,249.7 29,536.8 27,888.5

Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50,899.7

Cipla Ltd. 52,876.20 56,704.00 63,850.70 68,477.0

Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0

Dr. Reddy’s Laboratories(DRL)

69,441.00 70,277.00 74,693.00 96,737.4




GlaxosmithKlineConsumer Healthcare

Ltd.19,757.6 23,693.3 27,688.6 28,857.3

Glenmark

Pharmaceuticals Ltd. 21,241.20 25,291.30 29,490.70 40,206.4

Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5

Lupin Ltd. 38,508.30 48,318.10 57,851.90 70,829.1

Nestle India Ltd. 51,395.5 62,609.4 74,994.6 77,409.0

Opto Circuits (India) Ltd. 8,185.197 10,775.826 15,855.631 23,568.543

Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3

Ranbaxy LaboratoriesLtd. 75,970.40 89,607.70 101,614.1 117,153.2

Siemens India Ltd. 93,070.2 96,272.4 119,718.1 124,657.9

Strides Arcolab Ltd. 13,101.6 16,958.4 25,245.2 25,645.1

Sun Pharmaceuticals

Industries Ltd.42,723.00 38,086.30 57,214.30 80,056.6

Torrent Pharmaceuticals

Ltd.16,306.60 19,160.40 22,264.80 26,959.2

Wockhardt Ltd. 3,6294.4* 36,477.60 37,633.50 46,138.0

Annual Financial Results – Income (INR mn) - Major Healthcare

Companies

Companies F Y ’09 FY ’10 FY ’11 FY’ 12

Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0

Blue Star Ltd. 1,802.9 2,114.9 1,609.6 ‐1,051.0

Cadila Healthcare Ltd. 3,031.00 5,051.00 7,110.00 6,525.9

Cipla Ltd. 7,710.20 10,825.90 9,895.70 11,442.4

Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0




Dr. Reddy’s Laboratories(DRL)

‐5,168.00 1,068.00 11,040.00 14,262.1

GlaxoSmithKline Consumer

Healthcare Ltd.2,327.8 2,998.5 3,552.1 3,765.6

Glenmark Pharmaceuticals

Ltd.1,916.60 3,244.70 4,532.10 4,603.5

Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6

Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5

Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7



Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5

Siemens India Ltd. 7,046.0 7,577.7 8,677.5 7,300.6

Strides Arcolab Ltd. 1,096.80 1,224.50 2,244.8 8,258.4

Sun PharmaceuticalsIndustries Ltd.

18,177.30 13,510.80 18,160.60 25,872.5

Torrent Pharmaceuticals Ltd. 1,843.70 2,312.00 2,701.70 2,840.4

Wockhardt Ltd. ‐4,355.4* ‐9,804.20 905.2 3,427.1




Quarterly Financial Results – Revenue (INR mn) – Major Healthcare

Companies Companies

Jul-Sep

2011

Oct -Dec

2011

Jan-Mar

2012

Apr-Jun

2012

Biocon Ltd. 5,084.40 5,171.90 5,892.2 5,770.0

Blue Star Ltd. N.A. 5,896.9 N.A. N.A.

Cadila Healthcare Ltd. 12 0,196.4 13,524.60 14 .9,633 15 .0,161

Cipla Ltd. N.A. 17,580.00 N.A N.A.

Dabur India Ltd. 12,623.30 14,526.80 13,858.3 14,620.0

Dr. Reddy’s Laboratories

(DRL)22,678.00 27,692.00 26,584.0 25,406.0

GlaxoSmithKline ConsumerHealthcare Ltd.

7,200.7 6,854.0 8,608.7 7,869.6


Ltd.10,554.50 10,310.90 10,751.2 10,404.1

Jubilant life Sciences Ltd. 10,480.80 10,871.70 12,235.9 12,358.9

Lupin Ltd. 17,416.6 17,917.0 20,063.7 22,191.5

Nestle India Ltd. 19,631.00 19,633.2 20,558.7 19,865.8



Ranbaxy Laboratories Ltd. 20 .3,955 37 .1,923 36,954.0 31 .6,740

Siemens India Ltd. N.A. N.A. 37 2601.43 N.A.

Strides Arcolab Ltd 7,693.10 6,864.7 5,274.7 5,082.9

Sun PharmaceuticalsIndustries Ltd. 18,946.00 21,451.30 23,299.3 26,581.4

Torrent Pharmaceuticals Ltd 6,833.3 6,965.9 6,686.8 7,356.0

Wockhardt Ltd. 11,105.30 12,086.70 12,413.90 14,258.2




Quarterly Financial Results – Income (INR mn) - Major Healthcare

Com anies

Companies

Jul-Sep

2011

Oct -Dec

2011

Jan-Mar

2012

Apr-Jun

2012

Biocon Ltd. 857.0 848.50 978.0 790.0

Blue Star Ltd. N.A. (327.6) N.A. N.A.

Cadila Healthcare Ltd. 1,0 026.8 1,492.10 1, 8708. 1, 9947.

Cipla Ltd. N.A. 2,699.10 N.A. N.A.

Dabur India Ltd. 1,738.6 1,728.20 1,705.1 1,494.0

Dr. Reddy’s Laboratories

(DRL)3,078.0 5,130.0 3,427.0 3,360.0

GlaxoSmithKline ConsumerHealthcare Ltd.

1,030.3 591.0 1,319.7 1,066.0


Ltd.558.6 461.20 1,482.7 782.8

Jubilant life Sciences Ltd. 793.6 ‐783.90 ‐635.3 50.1

Lupin Ltd. 2,668.70 2,350.60 1,556.4 2,803.9

Nestle India 2,611.80 2,308.30 2,757.3 2,459.7


Piramal Healthcare Ltd. 524.3 85.2 ‐386.8 40.8

Ranbaxy Laboratories Ltd. ‐4,645.8 ‐29 .7,827 12,467.6 ‐5,857.3

Siemens India Ltd. N.A. N.A. 3,040.0 N.A.

Strides Arcolab Ltd 464.7 684.1 6,420.7 904.8

Sun Pharmaceuticals

Industries Ltd.5,977.4 6,683.0 8202.1 7,955.5

Torrent Pharmaceuticals Ltd 999.9 831.8 ‐16.5 1,018.5

Wockhardt Ltd. 1,275.80 2,128.10 ‐1,916.4 3,779.7

* denotes a change in financial year




Events Calendar

Pre-Conference Workshops & International

Confer E-BASED HEALTHCARE ence on EVIDENC

Date: 6

th – 8enue:

th Oct, 2012V India International Centre, New DelhiOrganize All India

(AIIMS)

r: Clinical Epidemiology Unit of Institute of Medical Sciences

Website: ht tp://www.isehcon2012.com d

Contact 434

Contact Person: Dr. Kameshwar Prasa6588

Fax No. 8641

No.: +91‐11‐26594436/2: +91‐11‐26588663/2658

Email: [email protected]

Pharm mpliance Summit 2012 a Legal & Co

Date: 5

th OVenue: H mbai

ct, 2012

Organize

otel Holiday Inn, Mur: Lex Witness

Website: www.plcs2012.com Contact Person: 01143440000Contact No. : +91‐8800841600Email: [email protected]

Research on India (ROI) is a leading source for market research on various sectors in India

hat offers premium research content from worldwide publishers of market researcht reports.

Contact us:

mW: https://www.researchonindia.co

; International: +91 (33) 4027 6214/5T

E

: India (Toll Free): 1800 102 1133

: [email protected]

Connect with Us

Disclaimer: This monthly update is published for general information only based on press articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document.


http://www.isehcon2012.com/




mailto:[email protected]








http://www.linkedin.com/groups?gid=3280715&trk=hb_side_g

https://twitter.com/ResearchOnIndia

http://www.facebook.com/researchonindia




healthcare sector in india monthly update september 2012

Documents